chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Body aches; Chills; Headache; Fever of 103.6; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Body aches), CHILLS (Chills), HEADACHE (Headache) and PYREXIA (Fever of 103.6) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (Body aches), CHILLS (Chills), HEADACHE (Headache) and PYREXIA (Fever of 103.6). At the time of the report, MYALGIA (Body aches), CHILLS (Chills), HEADACHE (Headache) and PYREXIA (Fever of 103.6) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 103.6 (High) Fever of 103.6.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication list was not provided. Treatment information was not provided.
This solicited report received from a consumer. Analysis to support the Real time signal evaluation in response to ongoing routine PV monitoring "PRIVATE" concerned a 27 year old female of an unspecified race and ethnicity. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient was not pregnant at the time of vaccination. The patient initiated treatment with Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry were not reported) dose, start therapy date were not reported, 1 total administered for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient received J &J vaccine 2 weeks prior presenting to emergency department. Three days prior the patient noticed petechiae on legs and followed up with primary care physician and referred to hematologist after platelets were drawn and were less than 1000. Hematology department again redraw and was 2000. Hematology then send to emergency department and requested starting IVIG (Intravenous immunoglobulin) and to be admitted. Received IVIG (Intravenous immunoglobulin). The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. The outcome of acute idiopathic thrombocytopenic purpura was not reported. The reporter considered the causality between Covid-19 vaccine ad26.cov2.s, and acute idiopathic thrombocytopenic purpura as related. The company causality between Covid-19 vaccine ad26.cov2.s, and acute idiopathic thrombocytopenic purpura as related This report was serious (Other Medically Important Condition). Sender's Comments: V0-20220326336-Covid-19 vaccine ad26.cov2.s- Acute idiopathic thrombocytopenic purpura. This event(s) is labeled per RA and is therefore considered potentially related.
Felt achy for about 24 hrs; His arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Felt achy for about 24 hrs) and PAIN IN EXTREMITY (His arm was sore) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes. Concomitant products included INSULIN for Diabetes.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Mar-2021, the patient experienced PAIN (Felt achy for about 24 hrs) and PAIN IN EXTREMITY (His arm was sore). At the time of the report, PAIN (Felt achy for about 24 hrs) and PAIN IN EXTREMITY (His arm was sore) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Treatment medications were not reported.   This case was linked to MOD-2021-406787 (Patient Link).
This case was reported by a consumer via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 67-year-old female patient who received SHINGRIX for prophylaxis. Concomitant products included PNEUMONIA VACCINE. On 10th October 2018 12:00, the patient received the 1st dose of SHINGRIX (intramuscular). In October 2018, less than a week after receiving SHINGRIX, the patient experienced extensive swelling of vaccinated limb, fever, nausea, burning sensation, erythema of extremities, tingling of extremity, influenza-like symptoms and headache. In October 2018, the outcome of the fever, nausea, influenza-like symptoms and headache were recovered/resolved. On an unknown date, the outcome of the extensive swelling of vaccinated limb, burning sensation, erythema of extremities and tingling of extremity were recovering/resolving. It was unknown if the reporter considered the extensive swelling of vaccinated limb, fever, nausea, burning sensation, erythema of extremities, tingling of extremity, influenza-like symptoms and headache to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on the right arm and Pneumonia vaccine on the left arm both on same day. Around midnight on the day of vaccination, the patient experienced fever, flu like symptoms, nausea and headache. The symptoms got worse on Thursday followed by Friday, and resolved by Saturday. The patient also experienced redness and swelling of the arm, along with tingling and burning sensation on the arm. The redness and swelling went from shoulder down to the elbow. The patient denied permission to contact their physician. No further details were provided.
17 hours after receiving H1N1 vaccine and 1.5 hours after waking and eating breakfast experiencing tingling sensation in fingers of right hand moving up the right arm into the right tongue. Reports swelling of right side of tongue. Signs & symptoms resolve in 30 minutes.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. Pharmacist mentioned a shipment of ZOSTAVAX and (Merck) VARIVAX were received with a 4 days shipping time period were given to patients (unknown date). Pharmacist stated the shipment was received and the ice packs were still frozen and the ZOSTAVAX and (Merck) VARIVAX were stored in the freezer. There were 9 patients who received ZOSTAVAX. On 11-FEB-2013, one of them was vaccinated with a dose of ZOSTAVAX lot # H019040, Expire date: 17-JAN-2014 (route and dose not reported). No concomitant medication were reported. The patient was not experiencing any known symptoms. Patient's outcome was unknown. This is one of several reports from the same source. Additional information has been requested.
cold sore; body aches; They have worsened as the day went on; stress; This is a spontaneous report from a contactable other healthcare professional (patient, Physical Therapist) from a Pfizer-sponsored program. A 29-year-old female patient received her second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EL3248), via an unspecified route of administration on 06Jan2021 at single dose for COVID-19 immunization. Medical history included cold sores. Concomitant medication included valaciclovir hydrochloride (VALTREX) from 2009 and ongoing for cold sores, ongoing fluticasone propionate (FLONASE ALLERGY RELIEF), ethinylestradiol, ferrous fumarate, norethisterone acetate (BLISOVI FE 1/20) from 2006 and ongoing for birth control. The patient previously received first dose of (PFIZER-BIONTECH COVID-19 VACCINE, lot number EH9899) on 15Dec2020 for COVID-19 immunization and experienced fever and body aches. The reporter wanted to verify if it was an interaction. She didn't feel like it was a drug interaction. She was questioning if there could be a drug interaction. She took Valtrex for cold sores on her face. She received her second dose of the COVID vaccine yesterday on 06Jan2021. Today 07Jan2021, she got a cold sore this morning and took Valtrex. She was wondering if the Valtrex, being an antiviral, could affect the vaccine in any way. She got the cold sores randomly anyway. They come on because of stress. She has a history with them. Caller didn't have a prescribing doctor. She got the vaccine through work. This time for second dose she developed body aches only. She received the vaccine yesterday 06Jan2021, and developed body aches today 07Jan2021. They have worsened as the day went on, but she was at work. Since she was home now and not moving around as much they weren't as bad. She got the vaccine because she worked in a nursing home. She was an essential worker who was at high risk. The outcome of events was unknown.
Information has been received from a physician's assistant concerning a 39 year old female with an allergy to ofloxacin (FLOXIN) who on 14-JUN-2006 received a 0.1 mL dose of Pneumovax 23 intradermally instead of tuberculin purified protein derivative skin testing in error. When the patient woke up the morning of 15-JUN-2006, the patient's arm was very sore. The patient had a 5 cm erythematous area at the injection site. She felt tightness on her chest and started coughing by lung time. The patient sought unspecified medical attention. An electrocardiogram was normal. The patient's inflammation resolved in 72 hours, and the patient subsequently recovered. No additional information is expected.
Vomiting; diarrhoea; This is a spontaneous report from a contactable consumer (patient). A non-pregnant 61-year-old female patient received BNT162B2 (PFIZER-BIOTECH COVID-19 VACCINE, solution for injection), dose 1, via an unspecified route of administration, administered on right arm on 10Mar2021 (Lot number: EN6208) as 1st dose, single dose for COVID-19 immunization. The patient's medical history was not reported. The patient's concomitant medication included cetirizine hydrochloride (ZYRTEC), escitalopram oxalate (LEXAPRO Strength: 5mg), and trazadone 50mg. The patient's known allergies included cefalexin monohydrate (KEFLEX), minocycline, and NSAIDS. On 12Mar2021 at 23:45, the patient experienced vomiting and diarrhea. The patient received no treatment for the events. The outcome of the events was recovering.    No follow-up attempts are possible. No further information is expected.
Fever 103F starting the first day after vaccine administered and continuing for 3 days.  Rash started on the third day of fever.  Low WBC and platelets noted on 8/6/2010 when patient was admitted to the hospital for prolonged fever symptoms.  Patient was started on IV Ceftriaxone as a precaution upon admission to the hospital and was continued for 5 days of therapy.
Pt exp chills, inc t104, loss of balance inc respirations in 60's;
Site: Bruising at Injection Site-Mild, Systemic: Allergic: Difficulty Breathing-Mild, Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild, Systemic: Allergic: Itch (specify: facial area, extremeties)-Mild, Systemic: Body Aches Generalized-Severe, Systemic: Chest Tightness / Heaviness / Pain-Severe, Systemic: Chills-Medium, Systemic: Dizziness / Lightheadness-Severe, Systemic: Fainting / Unresponsive-Severe, Systemic: Nausea-Medium, Systemic: Shakiness-Severe
Got my 1st dose in May and I haven't had time to go get my 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Got my 1st dose in May and I haven't had time to go get my 2nd dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Got my 1st dose in May and I haven't had time to go get my 2nd dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Got my 1st dose in May and I haven't had time to go get my 2nd dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The concomitant medications were not reported. The treatment information was not provided.
pt recvd vax & exp nausea, fatigue & fever which persisted for almost one wk; pt seen by MD who dx viral infection;
Clinical presentation of chicken pox started on 6/14/14 - seen in office and diagnosed based on physical exam 6/16/14. (Fever, pruritic vesicles/lesions in different stages in diffuse distribution).
Localized redness (Injection site reaction, injection site reaction)(Inject site react) - recovered/resolved Localized tenderness (Injection site pain, Injection site pain)(pain inject site) - recovered/resolved Received sub-optimal dose (Medication error, medication error)(Med error) - not reported Administration by an unlicensed route (Medication error, medication error) (Med error) - not reported A report was received from a health care professional on 11 November 2003 concerning a 35 year old male vaccinee who experienced localized redness an unspecified length of time after inadvertently receiving a sub-optimal dose of Fluvirin intradermally on 11 November 2003. On 11 November 2003 the vacinee received 0.1ml Fluvirin intradermally. The vaccinee experinced injection site redness shortly after vaccination. The vaccinee had not recovered at the time of the report. There was insufficient information to determine the reporter's causality assessment. Update 1 25 November 2003 Follow-up information recieved from a health care professional indicated that the vacinee also experienced localized tenderness on 11 November 2003. The vacinee recovered on 17 November 2003.
Intense abdominal pain that required hospitalization from Sunday, May 16, 2021 until Friday, May 28, 2021 due to portal vein thrombosis as well as other abdominal blood clots.  No clots were found in extremities and no genetic reason for occurrence.  Patient left hospital with Xarelto medication for thrombosis treatment.  Patient is still under medical care by hematologist and primary care physician to date for treatment of the blood clots.
First dose on 2019, 2nd dose on 2021; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 15th May 2019).   On 27th December 2021, the patient received the 2nd dose of Shingrix. On 27th December 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.  Additional details were provided as follows: The age at vaccination was not reported. No lot number and expiration date provided. The pharmacist student reported that, the patient received a second dose of shingrix outside recommended schedule, which led to lengthening of vaccination schedule.  No known side effect was reported. The reporter consented to follow up. No patient's identifiers were provided. No Lot number and expiration date provided
Patient presented to the ED for left-sided facial weakness which started the day before time of presentation.  He denies headache, fever, chills, night sweats, chest pain, shortness of breath, palpitations, syncope, or other symptoms.  The patient has a history of hypertension for which he is on amlodipine.  He has a prior history of prostate cancer diagnosed in 2010 and a prior history of breast cancer diagnosed in 2004.  He has a right inguinal hernia, but he decided not to pursue treatment at this point. Patient admitted for CVA, upon testing for SNF placement pt came back COVID + on 1/21/22.  Pt remained asymptomatic until d/c on 1/24/22. Pt vaccinated with Janssen on  6/18/21.
Excessive , uncontrollable bleeding; This is a spontaneous report from a contactable consumer (patient).    A 35-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, expiration date not provided), 2nd dose via an unspecified route of administration, administered in Arm Left on 16Mar2021 (Lot Number: EW0151) at age of 34 years old as a single dose for covid-19 immunisation. The patient was not pregnancy at time of vaccination. Medical history included anxiety. Concomitant medication included paroxetine hydrochloride (PAXIL).  The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date not provided), 1st dose via an unspecified route of administration, date as a single dose for covid-19 immunisation and No reaction on previous exposure to drug. The patient experienced excessive, uncontrollable bleeding on 27May2021 18:15 with outcome of recovering.  The patient was hospitalized for the event for 3 days. The patient underwent lab tests and procedures which included Nasal swab: negative on an unknown date. The patient received Blood transfusion and Premarin as treatment for the event. The event was resulted to visit Emergency room/department or urgent care. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient didn't received any other vaccines within 4 weeks prior to the COVID vaccine.  Information on the lot/batch was available, further information has been requested.
Patient here in clinic for PPD reading; noted varicella administered 6-25-13 in right arm, noted redness, swelling, c/o itching on 6-26-13. Patient stated applied ice pack, hydrocortisone cream, swelling and itching.
Same day as vaccine (Wednesday): expected achy arm, spreading to aching all over. Overnight (Wednesday night): Woke in the night with aches strong enough to prevent me from sleeping. Near-hallucination sensations of being able to "feel" my body warring with my left arm (injection site). Able to stand and walk around. Fever unknown. Next day (Thursday): Extreme fatigue, slept most of the day. Unable to stand for very long before the world started to go grey as if I was going to faint (I always sat down before I had a chance to faint). Feeling of breathlessness as if I was at a higher altitude than usual. Home O2 monitor repeatedly read at 97% throughout the day. Low-grade fever of 100.7ºF. Nauseous. Friday: Able to stand for longer but not indefinitely before the world went grey. Limbs and extremities easily got pins-and-needles tingling sensation after a couple moments of rest. Saturday: Hands tingling without any rest or constriction. Able to stand and walk. Still fatigued, still a bit breathless. Sunday: Tingling better but still present. Still fatigued. Breathlessness gone, standing nearly normal but still tiring. [Next few days too vague to describe, but symptoms are mostly gone by the following Wednesday except for occasional tingling in hands and arms.]
Injection completed at approximetly 1146.  Patient sat up in chair whie documentation completed.   Approximetly 1146 AM, patient stated, "Whoa! I feel a little dizzy."  Patient instructed to rest head and take deep breaths while I went to grab an ice pack approximetly 20 feet away .  Upon return, patient noted to be slumped in chair, head extended and back.  Eyes open. No audible sound of air exchange noted.  Patient did not respond to verbal commands or physical stimulation.  Head assisted and held in flexed position to move tongue, which was obstructing airway.  Skin tone pale, cool, clammy.  Pharmacist entered room.  Audible breathing spontaneously resumed.  Patient responded to verbal command.  Pharmacist instructed him to consume water.  Ice pack applied to back of neck with cool, damp papertowel offered to wipe brow and apply to neck/face.  Patient oriented to self, situation at 1148.  Patient instructed to place head down and take slow, deep breaths.  Patient able to hold regular conversation, answer questions and ambulate around office without difficulty or any sign of orthostatic hypotension noted.  Patient able to sit and stand without vasovagal syncope occurring at 11:55pm.  Patient sat in office with me for 20 more minutes to ensure return to homeostasis occurred as much as possible.  Patient d/c at 12:25 pm.
I had chills, fever, headache, pain in lungs, cough, pain in abdoman, pain in intestines, vomiting, weak. had to be in bed 8 days
LEFT ARM RED AND WARM TO TOUCH @ SITE OF IMMUNIZATIONS. AFEBRILE.
Patient received Pfizer COVID vaccine on 3/2/21 and 4/24/21. On 1/29/22, patient admitted to our inpatient facility with acute hypoxic respiratory failure secondary to COVID19 pneumonia. Patient was discharged home in good condition the next day 1/30/22.
COVID vaccine breakthrough case. Pfizer EL9267 2/20/21, EN6200 3/13/21, and boosted FF8841 10/05/21
Bruising about the size of a nickel with multiple red dots around the perimeter.  Lasted about 3 weeks but now almost gone.  No pain or sickness; just the bruising.
Information has been received from a registered nurse concerning a male who last week was vaccinated with VARIVAX (Merck). Concomitant therapy included FLUZONE. The patient experienced difficulty breathing, hives, cough and facial edema. Additional information has been requested.
Itchy rash all over back, shoulders, arms. Red spots; look something like measles or shingles. Applying Triamcinolone Acetonide cream,  per dermatologist. Applied for 3 days at time of reporting. Symptoms, signs about the same.
I received my first Covid vaccine dose on 8/10/21 and had my period on 8/16/21. Then I had my second dose on 9/8/21 and to this day (11/11/21) I have still not gotten my period since August. I had a blood test to check for pregnancy and it came back negative, so I believe this was caused by the vaccine. Along with amenorrhea, I also have severe intermittent cramping in my lower abdomen.